Sign In
Buy INSM
$103.86
+0.130 (+0.125%)
At Close: Jun 03, 2026
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
07:00am, Thursday, 04'th Jun 2026
BRIDGEWATER, N.J., June 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Insmed to Present at the 2026 Goldman Sachs Annual Global Healthcare Conference
07:00am, Wednesday, 27'th May 2026
BRIDGEWATER, N.J., May 27, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform
Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
12:50pm, Wednesday, 20'th May 2026
Insmed Incorporated (INSM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Insmed CEO Defends BRINSUPRI Launch as Sales Surge, TPIP Pipeline Gains Focus
03:04am, Monday, 18'th May 2026
Insmed NASDAQ: INSM Chair and CEO Will Lewis said the company remains confident in the launch trajectory of BRINSUPRI, despite investor concerns over discontinuation rates that followed the company's
Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
07:20pm, Tuesday, 12'th May 2026
Insmed Incorporated (INSM) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Insmed's Q1 Earnings Beat, Sales Miss Estimates, Stock Tanks 23%
11:06am, Friday, 08'th May 2026
INSM stock plunges 23% after Q1 sales miss estimates despite 230% revenue growth and strong Brinsupri uptake.
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
02:51pm, Thursday, 07'th May 2026
Insmed Incorporated (INSM) Q1 2026 Earnings Call Transcript
Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish
11:03am, Thursday, 07'th May 2026
Insmed stock tanked Thursday after its new lung drug, Brinsupri, missed elevated buy-side expectations, though beat sell-side views.
Insmed (INSM) Reports Q1 Loss, Misses Revenue Estimates
09:56am, Thursday, 07'th May 2026
Insmed (INSM) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.9. This compares to a loss of $1.42 per share a year ago.
Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update
07:00am, Thursday, 07'th May 2026
— Total Company Revenues of $306.0 Million for the First Quarter of 2026— —BRINSUPRI ® (brensocatib) Revenues of $207.9 Million for the First Quarter of 2026, Reflecting 44% Growth Over the Fou
Insmed and Ty Pennington Team Up to Drive Awareness and Proper Diagnosis of Bronchiectasis
04:30pm, Wednesday, 06'th May 2026
— Insmed's Educational Initiative, Suspect Bronchiectasis (Suspect BE), Aims to Elevate Recognition and Diagnosis of Bronchiectasis and Encourage Conversations with a Pulmonologist — — Bronchie
—New Data in Non-Cystic Fibrosis Bronchiectasis Further Define Impact of BRINSUPRI ® on Respiratory Symptoms— —Findings from a Pharmacokinetic Study Continue to Support Further Evaluation of Tr
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Thursday, 30'th Apr 2026
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed to Present at May 2026 Investor Conferences
07:00am, Thursday, 30'th Apr 2026
BRIDGEWATER, N.J., April 30, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
Insmed to Host First-Quarter 2026 Financial Results Conference Call on Thursday, May 7, 2026
07:00am, Thursday, 23'rd Apr 2026
BRIDGEWATER, N.J., April 23, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transfor
